发明名称 Process for preparing cannabinoid receptor ligands
摘要 A process for the preparation of compounds of formula (I) or a salt thereof; wherein X1, X2, X3, X4, Rx, u, R2, R1g, z, and A1 are as defined in the specification is disclosed.
申请公布号 US8816086(B2) 申请公布日期 2014.08.26
申请号 US201012969047 申请日期 2010.12.15
申请人 AbbVie Inc. 发明人 Pu Yu-Ming;Christesen Alan;Cullen Steven;Ku Yi-Yin
分类号 C07D513/04;A61K31/4365 主分类号 C07D513/04
代理机构 Michael Best & Friedrich LLP 代理人 Mueller Lisa V.;Michael Best & Friedrich LLP
主权项 1. A process for preparing a compound of formula (Ib) or (IIIa)or salt thereof, wherein R1g, at each occurrence, is each independently chosen from the group consisting of G1d, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen, C1-C4 haloalkyl, —CN, —ORf, —OC(O)Rf, —OC(O)N(Rf)2, —S(O)2Re, —S(O)2N(Rf)2, —C(O)Rf, —C(O)ORf, —C(O)N(Rf)2, —N(Rf)2, —N(Rf)C(O)Rf, —N(Rf)S(O)2Re, —N(Rf)C(O)O(Re), —N(Rf)C(O)N(Rf)2, —(CR1cR1d)q3—ORf, —(CR1cR1d)q3—OC(O)Rf, —(CR1cR1d)q3—OC(O)N(Rf)2, —(CR1cR1d)q3—S(O)2Re, —(CR1cR1d)q3—S(O)2N(O2, —(CR1cR1d)q3—C(O)Rf, —(CR1cR1d)q3—C(O)ORf, —(CR1cR1d)q3—C(O)N(Rf)2, —(CR1cR1d)q3—N(Rf)2, —(CR1cR1d)q3—N(Rf)C(O)Rf, —(CR1cR1d)q3—N(Rf)S(O)2Re, —(CR1cR1d)q3—N(Rf)C(O)O(Re), —(CR1cR1d)q3—N(Rf)C(O)N(Rf)2, and —(CR1cR1d)q3—CN; Re, at each occurrence, is independently C1-C4 alkyl, C1-C4 haloalkyl, monocyclic cycloalkyl, or —(CR1cR1d)q3-(monocyclic cycloalkyl); Rf, at each occurrence, is independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, —(CR1cR1d)q3—ORg, monocyclic cycloalkyl, or —(CR1cR1d)q3-(monocyclic cycloalkyl); Rg, at each occurrence, is independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, monocyclic cycloalkyl, or —(CR1cR1d)q3-(monocyclic cycloalkyl); A2 is N(Rb)(Rc), G1c, or —(CR1aR1b)q-G1c; G1c is a monocyclic heterocycle or a monocyclic cycloalkyl wherein each ring is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of oxo, alkyl, alkenyl, alkynyl, halogen, haloalkyl, —CN, alkoxy, haloalkoxy, —C(O)OH, and —C(O)O(alkyl); R2 is C2-C10 alkyl, alkenyl, alkynyl, haloalkyl, —(CR2aR2b)q4—O—Ra, —(CR2aR2b)q4—O G2a, —(CR2aR2b)q4—O(CR2cR2d)q5-G2a, —(CR2aR2b)q5—C(O)—Ra, —(CR2aR2b)q5—C(═N—ORe)Ra, —(CR2aR2b)q5—SO2—Rd, —(CR2aR2b)q5-G2a, —(CR2aR2b)q5—C(O)N(Rb)(Rc), —(CR2aR2b)q4—OC(O)N(Rb)(Rc), or —(CR2aR2b)q5—CN; G2a, at each occurrence, is independently cycloalkyl, cycloalkenyl, heterocycle, aryl, or heteroaryl; wherein each of the rings as represented by G2a is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of oxo, alkyl, halogen, hydroxy, alkoxy, haloalkoxy, and haloalkyl; Ra and Rc, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, —(CR1aR1b)q2—ORh, —(CR1aR1b)q2—N(Rh)2, G1d, or —(CR1aR1b)q2G1d; Rb, at each occurrence, is independently hydrogen, alkyl, haloalkyl, alkoxyalkyl, monocyclic cycloalkyl, —(CR1cR1d)q2-(monocyclic cycloalkyl), or haloalkoxyalkyl; Rd, at each occurrence, is independently alkyl, haloalkyl, —(CR1aR1b)q2—ORh, —(CR1aR1b)q2—N(Rh)2, G1d, or —(CR1aR1b)q2-G1d; G1d, at each occurrence, is independently a monocyclic heterocycle, a monocyclic heteroaryl, a phenyl, a monocyclic cycloalkyl, or a monocyclic cycloalkenyl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of —N(R)2, —CN, oxo, alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, and hydroxy; Rh, at each occurrence, is independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, monocyclic cycloalkyl, or —(CR1cR1d)q3-(monocyclic cycloalkyl) wherein the monocyclic cycloalkyl, as a substituent or part of a substituent, of Rb, Re, Rf, Rg, and Rh, at each occurrence, is independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of C1-C4 alkyl, halogen, oxo, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, and C1-C4 haloalkyl; q, q1, and q2, at each occurrence, are each independently 1, 2, 3, or 4; R1a, R1b, R1c, R1d, R2a, R2b, R2c, and R2d, at each occurrence, are each independently hydrogen, halogen, C1-C4 alkyl, or C1-C4 haloalkyl; q3, at each occurrence, is independently 1, 2 or, 3; q4, at each occurrence, is independently 2, 3, 4, or 5; q5, at each occurrence, is independently 1, 2, 3, 4, 5, or 6; z is 0, 1, 2, 3, or 4; one of X1, X2, X3, and X4 is N and the others are CH; u is 0, 1, 2, or 3; and each Rx is an optional substituent on any substitutable carbon atom, and is independently selected from the group consisting of alkyl, halogen, hydroxy, alkoxy, haloalkoxy, and haloalkyl; comprising the steps of (1a) treating a compound of formula (IV) wherein R2v is halogen or sulfonate; and R3v is halogen or OH; with a thiocyanate source to produce a compound of formula (V) (1b) reacting a compound of formula (V) with a compound of formula (VI) wherein R4v is halogen or sulfonate to produce a compound of formula (II) or a salt thereof (2a) treating a compound of formula (II) or a salt thereof with a compound of formula HO—(CR1aR1b)q1—O—Rp or HO-A2, or a salt thereof, wherein Rp is hydrogen or a hydroxy-protecting group; to produce a compound of formula (IIIa) or (IIIb), or a salt thereof (2b) deprotect a compound of formula (IIIb) or a salt thereof wherein Rp is a hydroxy-protecting group to form a compound of formula (Ib) or a salt thereof
地址 North Chicago IL US